Insulin degludec/Insulin aspart

德谷胰岛素/门冬胰岛素

Report date: 2026/05/26 20:00:28

Base Information

Drug NameInsulin degludec/Insulin aspart
Drug Alias Name德谷门冬双胰岛素Ryzodeg诺和佳NN-1045NN-5401 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryJapan
Original Approved Date2012/12/25
Country/TerritoryUnited StatesSwedenTaiwan +[20] 
CombinationsYes Insulin aspartInsulin degludec
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/S
Inactive CompaniesNovo Nordisk (China)Pharmaceuticals Co Ltd
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AD06
Related LinksKEGG